Magovcevic-Liebisch Ivana 4

What Happened
Ivana Magovcevic‑Liebisch, a director of Acrivon Therapeutics, was granted 9,366 restricted stock units (RSUs) on May 18, 2026. The RSUs were issued at $0.00 (a non‑cash compensation award) and represent contingent rights to receive one share of common stock per RSU upon vesting. The RSUs vest in full on May 18, 2027, subject to her continued service through that date. This is an award/compensation grant, not a purchase or sale.

Key Details

• Transaction date: 2026-05-18; Filing date: 2026-05-20 (Form 4 accession 0000905148-26-002559).
• Amount: 9,366 RSUs; reported acquisition price: $0.00 (RSU grant).
• Vesting: RSUs vest in full on May 18, 2027, contingent on continuous service (see footnote F1).
• Shares owned after transaction: not specified in this filing.
• Filing timeliness: filed two days after the grant date; appears to be timely (no late‑filing flag).
• No indication of a 10b5‑1 plan, tax withholding sale, gift, or immediate sale of shares in this report.

Context
RSUs are a form of equity compensation and convert into actual shares only upon vesting (subject to service and other conditions). Because this was a compensation grant (not a market purchase), it does not represent an immediate cash investment by the insider. Such awards are common for executives and directors as part of pay packages; they do not by themselves imply a buy or sell signal.